Cambrex Stock Price, News & Analysis (NYSE:CBM)

$51.95 0.00 (0.00 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$51.95
Today's Range$51.90 - $53.05
52-Week Range$42.55 - $62.95
Volume150,835 shs
Average Volume399,950 shs
Market Capitalization$1.71 billion
P/E Ratio16.76
Dividend YieldN/A
Beta2.38

About Cambrex (NYSE:CBM)

Cambrex logoCambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryLife Sciences Tools & Services
SectorHealthcare
SymbolNYSE:CBM
CUSIP13201110
Phone+1-201-8043000

Debt

Debt-to-Equity RatioN/A
Current Ratio5.11%
Quick Ratio3.44%

Price-To-Earnings

Trailing P/E Ratio16.758064516129
Forward P/E Ratio18.82
P/E Growth1.28

Sales & Book Value

Annual Sales$534.46 million
Price / Sales3.19
Cash Flow$4.15 per share
Price / Cash12.53
Book Value$16.59 per share
Price / Book3.13

Profitability

Trailing EPS$3.10
Net Income$102.45 million
Net Margins19.17%
Return on Equity22.42%
Return on Assets15.91%

Miscellaneous

Employees1,228
Outstanding Shares32,850,000

Cambrex (NYSE:CBM) Frequently Asked Questions

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) released its quarterly earnings data on Thursday, February, 8th. The biotechnology company reported $1.27 EPS for the quarter, topping the Zacks' consensus estimate of $1.10 by $0.17. The biotechnology company earned $182.28 million during the quarter, compared to analysts' expectations of $181.39 million. Cambrex had a net margin of 19.17% and a return on equity of 22.42%. The company's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.23 earnings per share. View Cambrex's Earnings History.

When will Cambrex make its next earnings announcement?

Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Cambrex.

What guidance has Cambrex issued on next quarter's earnings?

Cambrex updated its FY18 earnings guidance on Thursday, February, 8th. The company provided earnings per share guidance of $2.80-3.03 for the period, compared to the Thomson Reuters consensus estimate of $2.85. The company issued revenue guidance of $524-545 million (Down 2% to Up 2%), compared to the consensus revenue estimate of $538.50 million.

Where is Cambrex's stock going? Where will Cambrex's stock price be in 2018?

3 Wall Street analysts have issued 1-year price targets for Cambrex's shares. Their forecasts range from $60.00 to $60.00. On average, they expect Cambrex's share price to reach $60.00 in the next year. View Analyst Ratings for Cambrex.

Who are some of Cambrex's key competitors?

Who are Cambrex's key executives?

Cambrex's management team includes the folowing people:

  • Steven Mark Klosk, President, Chief Executive Officer, Director (Age 60)
  • Tom George Vadaketh, Chief Financial Officer, Executive Vice President (Age 54)
  • Shawn P. Cavanagh, Chief Operating Officer, Executive Vice President (Age 50)
  • Gregory P. Sargen, Executive Vice President, Corporate Development and Strategy (Age 51)
  • Samantha M. Hanley, Vice President, General Counsel,Corporate Secretary (Age 39)
  • James G. Farrell, Vice President and Corporate Controller (Age 50)
  • Shlomo Yanai, Non-Executive Chairman of the Board (Age 64)
  • Gregory B. Brown M.D., Director (Age 64)
  • Rosina B. Dixon M.D., Independent Director (Age 74)
  • Claes Glassell, Independent Director (Age 65)

Who owns Cambrex stock?

Cambrex's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.70%), William Blair Investment Management LLC (7.16%), Bank of New York Mellon Corp (4.53%), Congress Asset Management Co. MA (4.52%), Brown Advisory Inc. (2.73%) and Boston Partners (2.17%). Company insiders that own Cambrex stock include Gregory Sargen, Leon J Hendrix Jr, Louis J Grabowsky, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and William B Korb. View Institutional Ownership Trends for Cambrex.

Who sold Cambrex stock? Who is selling Cambrex stock?

Cambrex's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Kennedy Capital Management Inc., GW&K Investment Management LLC, BlackRock Inc., AlphaOne Investment Services LLC, Ranger Investment Management L.P., Penn Capital Management Co. Inc. and TrueNorth Inc.. Company insiders that have sold Cambrex company stock in the last year include Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex.

Who bought Cambrex stock? Who is buying Cambrex stock?

Cambrex's stock was purchased by a variety of institutional investors in the last quarter, including Brown Advisory Inc., William Blair Investment Management LLC, Lazard Asset Management LLC, Boston Partners, Peregrine Capital Management LLC, Mackenzie Financial Corp, Summit Creek Advisors LLC and Two Sigma Advisers LP. View Insider Buying and Selling for Cambrex.

How do I buy Cambrex stock?

Shares of Cambrex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cambrex's stock price today?

One share of Cambrex stock can currently be purchased for approximately $51.95.

How big of a company is Cambrex?

Cambrex has a market capitalization of $1.71 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.10 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.

How can I contact Cambrex?

Cambrex's mailing address is 1 Meadowlands Plz, E RUTHERFORD, NJ 07073-2150, United States. The biotechnology company can be reached via phone at +1-201-8043000 or via email at [email protected]


MarketBeat Community Rating for Cambrex (CBM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  265
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cambrex (NYSE:CBM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.673.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $60.00$60.50$62.33$65.67
Price Target Upside: 9.19% upside17.13% upside37.91% upside16.64% upside

Cambrex (NYSE:CBM) Consensus Price Target History

Price Target History for Cambrex (NYSE:CBM)

Cambrex (NYSE:CBM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018Longbow ResearchDowngradeBuy -> NeutralMediumView Rating Details
1/16/2018William BlairInitiated CoverageOutperform -> OutperformHighView Rating Details
10/31/2017Craig HallumReiterated RatingBuy$70.00 -> $60.00N/AView Rating Details
2/6/2017StephensSet Price TargetBuy$61.00N/AView Rating Details
1/17/2017First AnalysisBoost Price TargetOverweight$54.00 -> $66.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Cambrex (NYSE:CBM) Earnings History and Estimates Chart

Earnings by Quarter for Cambrex (NYSE:CBM)

Cambrex (NYSE CBM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$0.51N/AView Earnings Details
2/8/2018Q4 2017$1.10$1.27$181.39 million$182.28 millionViewN/AView Earnings Details
11/7/2017Q3 2017$0.47$0.55$108.44 million$112.60 millionViewN/AView Earnings Details
8/4/2017Q2 2017$0.76$0.76$136.82 million$134.55 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.51$0.68$99.05 million$105.01 millionViewListenView Earnings Details
2/3/2017Q416$1.05$1.23$174.53 million$178.70 millionViewListenView Earnings Details
11/4/2016Q3$0.41$0.47$96.07 million$99.90 millionViewListenView Earnings Details
7/28/2016Q216$0.59$0.68$114.85 million$118.22 millionViewListenView Earnings Details
4/29/2016Q116$0.34$0.50$83.61 million$94.74 millionViewListenView Earnings Details
2/9/2016Q4$0.83$0.53$152.94 million$156.90 millionViewListenView Earnings Details
11/3/2015Q3$0.38$0.40$101.09 million$92.97 millionViewListenView Earnings Details
7/30/2015Q215$0.44$0.63$110.03 million$106.40 millionViewListenView Earnings Details
5/1/2015Q115$0.23$0.29$76.01 million$78.20 millionViewListenView Earnings Details
2/6/2015Q414$0.50$0.60$117.90 million$128.80 millionViewListenView Earnings Details
10/30/2014Q314$0.29$0.28$94.25 million$81.10 millionViewListenView Earnings Details
8/12/2014$0.21$0.32ViewN/AView Earnings Details
8/1/2014Q214$0.28$0.32$92.70 million$98.00 millionViewListenView Earnings Details
5/2/2014Q114$0.23$0.05$79.40 million$66.20 millionViewListenView Earnings Details
2/11/2014Q4$0.30$0.30$95.25 million$103.00 millionViewListenView Earnings Details
11/1/2013Q313$0.21$0.20$83.60 million$78.00 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.26$0.10$73.70 million$61.60 millionViewListenView Earnings Details
5/3/2013Q1 2013$0.22$0.36$76.15 million$74.58 millionViewListenView Earnings Details
2/6/2013Q4 2012$0.13$0.26$68.30 million$69.93 millionViewListenView Earnings Details
11/5/2012Q312$0.12$0.07$61.00 million$59.21 millionViewN/AView Earnings Details
8/1/2012$0.21$0.33ViewN/AView Earnings Details
5/3/2012$0.14$0.24ViewN/AView Earnings Details
2/6/2012$0.12$0.10ViewN/AView Earnings Details
11/3/2011$0.07$0.10ViewN/AView Earnings Details
8/2/2011$0.13$0.16ViewN/AView Earnings Details
5/5/2011$0.08$0.10ViewN/AView Earnings Details
2/10/2011$0.10$0.16ViewN/AView Earnings Details
11/3/2010Q3 2010$0.09$0.02ViewN/AView Earnings Details
8/3/2010Q2 2010$0.11$0.12ViewN/AView Earnings Details
5/4/2010Q1 2010$0.11$0.06ViewN/AView Earnings Details
2/10/2010Q4 2009$0.05($0.09)ViewN/AView Earnings Details
11/3/2009Q3 2009$0.05$0.10ViewN/AView Earnings Details
8/4/2009Q2 2009$0.10$0.19ViewN/AView Earnings Details
5/5/2009Q1 2009$0.09$0.16ViewN/AView Earnings Details
2/11/2009Q4 2008$0.09$0.05ViewN/AView Earnings Details
11/4/2008Q3 2008$0.05$0.10ViewN/AView Earnings Details
8/5/2008Q2 2008$0.12$0.08ViewN/AView Earnings Details
5/1/2008Q1 2008$0.14$0.16ViewN/AView Earnings Details
2/14/2008Q4 2007$0.13$0.11ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cambrex (NYSE:CBM) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.47$0.47$0.47
Q2 20181$0.74$0.74$0.74
Q3 20181$0.57$0.57$0.57
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Cambrex (NYSE:CBM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cambrex (NYSE CBM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.48%
Insider Trades by Quarter for Cambrex (NYSE:CBM)
Insider Trades by Quarter for Cambrex (NYSE:CBM)

Cambrex (NYSE CBM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/2/2017Steven M KloskCEOSell4,000$54.96$219,840.0087,328View SEC Filing  
9/1/2017Steven M KloskCEOSell12,000$51.53$618,360.0095,328View SEC Filing  
8/1/2017Steven M KloskCEOSell12,000$61.39$736,680.0095,328View SEC Filing  
7/3/2017Steven M KloskCEOSell12,000$59.66$715,920.0095,328View SEC Filing  
6/12/2017Samantha HanleyVPSell14,000$57.56$805,840.001,500View SEC Filing  
6/6/2017Leon J Hendrix JrDirectorSell20,656$55.95$1,155,703.2074,662View SEC Filing  
6/1/2017Steven M KloskCEOSell12,000$54.19$650,280.0095,328View SEC Filing  
5/1/2017Steven M KloskCEOSell12,000$58.20$698,400.0095,328View SEC Filing  
4/3/2017Steven M KloskCEOSell12,000$54.58$654,960.0095,328View SEC Filing  
3/1/2017Steven M KloskCEOSell12,000$56.70$680,400.0095,328View SEC Filing  
2/27/2017Shawn CavanaghCOOSell19,620$55.95$1,097,739.0017,658View SEC Filing  
2/16/2017Steven M KloskCEOSell23,822$52.50$1,250,655.0094,241View SEC Filing  
2/13/2017Steven M KloskCEOSell63,178$52.55$3,320,003.90109,062View SEC Filing  
2/7/2017Gregory SargenEVPSell30,000$54.88$1,646,400.0050,000View SEC Filing  
2/7/2017Shawn CavanaghCOOSell20,380$55.12$1,123,345.6057,658View SEC Filing  
12/14/2016Shawn CavanaghCOOSell30,000$53.58$1,607,400.0027,658View SEC Filing  
11/11/2016Gregory SargenInsiderSell22,500$52.02$1,170,450.0027,500View SEC Filing  
7/11/2016William B KorbDirectorSell3,420$55.00$188,100.0023,982View SEC Filing  
6/8/2016William B KorbDirectorSell4,142$52.47$217,330.7424,704View SEC Filing  
6/1/2016William B KorbDirectorSell8,000$51.06$408,480.0025,304View SEC Filing  
5/9/2016Steven M KloskCEOSell14,005$49.00$686,245.00147,333View SEC Filing  
5/5/2016Steven M KloskCEOSell16,430$49.13$807,205.90136,828View SEC Filing  
5/3/2016William B KorbDirectorSell8,000$49.09$392,720.0032,562View SEC Filing  
3/16/2016Steven M KloskCEOSell19,565$41.00$802,165.00152,893View SEC Filing  
3/15/2016Louis J GrabowskyDirectorBuy750$40.10$30,075.00928View SEC Filing  
3/10/2016William B KorbDirectorSell8,000$41.38$331,040.0032,562View SEC Filing  
2/11/2016Gregory SargenCFOSell13,622$36.16$492,571.5246,697View SEC Filing  
2/11/2016Shawn CavanaghCOOSell18,342$36.13$662,696.4617,658View SEC Filing  
2/11/2016Steven M. KloskCEOSell39,542$36.20$1,431,420.40133,328View SEC Filing  
12/15/2015Leon J. Hendrix, Jr.DirectorSell7,000$51.34$359,380.0071,211View SEC Filing  
12/11/2015Peter G. TombrosDirectorSell31,236$51.37$1,604,593.3221,520View SEC Filing  
11/30/2015Ilan KaufthalDirectorSell52,315$54.32$2,841,750.8060,000View SEC Filing  
11/13/2015Gregory SargenCFOSell28,750$49.14$1,412,775.0033,319View SEC Filing  
11/6/2015Samantha HanleyVPSell15,000$52.03$780,450.00View SEC Filing  
8/27/2015William B. KorbDirectorSell3,600$48.00$172,800.0046,562View SEC Filing  
5/21/2015Ilan KaufthalDirectorSell50,000$41.31$2,065,500.00View SEC Filing  
5/11/2015Gregory SargenCFOSell25,000$38.44$961,000.00View SEC Filing  
2/12/2015Aldo MagniniDirectorSell7,500$32.75$245,625.00View SEC Filing  
2/12/2015Gregory SargenCFOSell25,000$32.64$816,000.00View SEC Filing  
2/10/2015Steven M KloskCEOSell45,000$30.32$1,364,400.00View SEC Filing  
9/11/2014Shawn CavanaghCOOSell56,251$22.56$1,269,022.56View SEC Filing  
9/3/2014Steven M KloskCEOSell126,257$22.01$2,778,916.57View SEC Filing  
9/2/2014William M HaskelSVPSell9,400$21.94$206,236.00View SEC Filing  
8/19/2014Steven M KloskCEOSell4,702$22.00$103,444.00View SEC Filing  
8/7/2014Steven M KloskCEOSell1,200$22.52$27,024.00View SEC Filing  
8/7/2014William M HaskelSVPSell28,100$22.50$632,250.00View SEC Filing  
8/5/2014Gregory SargenCFOSell50,000$22.34$1,117,000.00View SEC Filing  
2/28/2014Leon Hendrix, Jr.DirectorSell23,000$20.09$462,070.0092,993View SEC Filing  
2/20/2014Aldo MagniniDirectorSell6,000$22.10$132,600.00View SEC Filing  
12/5/2013Paolo RussoloInsiderSell35,000$18.40$644,000.0067,085View SEC Filing  
11/11/2013Gregory SargenCFOSell20,000$18.92$378,400.0033,319View SEC Filing  
11/11/2013John MillerDirectorSell2,000$19.21$38,420.0035,306View SEC Filing  
5/24/2013Paolo RussoloInsiderSell32,903$12.53$412,274.59View SEC Filing  
5/16/2013Leon J Hendrix JrDirectorSell1,120$13.40$15,008.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cambrex (NYSE CBM) News Headlines

Source:
DateHeadline
Cleantech Building Materials: APPOINTMENT OF FINANCIAL ADVISER AND BROKERCleantech Building Materials: APPOINTMENT OF FINANCIAL ADVISER AND BROKER
finance.yahoo.com - February 20 at 5:15 PM
Contrasting Cambrex (CBM) & Veru (VERU)Contrasting Cambrex (CBM) & Veru (VERU)
www.americanbankingnews.com - February 18 at 12:08 PM
Cambrex Co. (CBM) Receives Average Rating of "Hold" from BrokeragesCambrex Co. (CBM) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 17 at 1:48 AM
Cambrex to Present at the 2018 RBC Capital Markets Global Healthcare ConferenceCambrex to Present at the 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 15 at 8:26 AM
Cambrex (CBM) Downgraded by Longbow ResearchCambrex (CBM) Downgraded by Longbow Research
www.americanbankingnews.com - February 15 at 12:52 AM
First Analysis Weighs in on Cambrex Co.s Q3 2018 Earnings (CBM)First Analysis Weighs in on Cambrex Co.'s Q3 2018 Earnings (CBM)
www.americanbankingnews.com - February 13 at 10:18 AM
Cleantech Building Materials: Thailand Distribution and Offtake AgreementCleantech Building Materials: Thailand Distribution and Offtake Agreement
finance.yahoo.com - February 9 at 9:30 AM
Blog Exposure - Verastem Reported Submission of NDA For Duvelisib for Treatment of Patients with Relapsed or Refractory CLL/SLL and Follicular LymphomaBlog Exposure - Verastem Reported Submission of NDA For Duvelisib for Treatment of Patients with Relapsed or Refractory CLL/SLL and Follicular Lymphoma
finance.yahoo.com - February 9 at 9:30 AM
Zacks: Brokerages Expect Cambrex Co. (CBM) Will Announce Quarterly Sales of $184.15 MillionZacks: Brokerages Expect Cambrex Co. (CBM) Will Announce Quarterly Sales of $184.15 Million
www.americanbankingnews.com - February 9 at 2:14 AM
Cleantech Building Materials: Amendment of Loan FacilityCleantech Building Materials: Amendment of Loan Facility
finance.yahoo.com - February 8 at 4:06 PM
Cambrex beats 4Q profit forecastsCambrex beats 4Q profit forecasts
finance.yahoo.com - February 8 at 4:06 PM
Is It Time To Buy Cambrex Corporation (NYSE:CBM)?Is It Time To Buy Cambrex Corporation (NYSE:CBM)?
finance.yahoo.com - February 8 at 4:06 PM
Cambrex (CBM) Issues Quarterly  Earnings ResultsCambrex (CBM) Issues Quarterly Earnings Results
www.americanbankingnews.com - February 8 at 10:58 AM
Cambrex (CBM) Updates FY18 Earnings GuidanceCambrex (CBM) Updates FY18 Earnings Guidance
www.americanbankingnews.com - February 8 at 9:00 AM
Cambrex Reports Fourth Quarter and Full Year 2017 Financial ResultsCambrex Reports Fourth Quarter and Full Year 2017 Financial Results
feeds.benzinga.com - February 8 at 7:45 AM
Cambrex beats by $0.15, misses on revenueCambrex beats by $0.15, misses on revenue
seekingalpha.com - February 8 at 6:49 AM
Cambrex to Announce Fourth Quarter and Full Year 2017 Financial Results on February 8, 2018Cambrex to Announce Fourth Quarter and Full Year 2017 Financial Results on February 8, 2018
finance.yahoo.com - February 2 at 9:28 AM
Estimating The Intrinsic Value Of Cambrex Corporation (NYSE:CBM)Estimating The Intrinsic Value Of Cambrex Corporation (NYSE:CBM)
finance.yahoo.com - February 1 at 4:07 PM
Cambrex Expands Process Research and Development Capabilities Across North AmericaCambrex Expands Process Research and Development Capabilities Across North America
finance.yahoo.com - January 30 at 9:59 AM
Cambrex (CBM) Set to Announce Earnings on ThursdayCambrex (CBM) Set to Announce Earnings on Thursday
www.americanbankingnews.com - January 25 at 1:44 AM
Cambrex Co. (CBM) Receives Average Recommendation of "Hold" from BrokeragesCambrex Co. (CBM) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 23 at 1:40 AM
 Brokerages Expect Cambrex Co. (CBM) Will Post Earnings of $1.10 Per Share Brokerages Expect Cambrex Co. (CBM) Will Post Earnings of $1.10 Per Share
www.americanbankingnews.com - January 21 at 3:22 PM
Cambrex Co. (CBM) Forecasted to Earn FY2017 Earnings of $2.96 Per ShareCambrex Co. (CBM) Forecasted to Earn FY2017 Earnings of $2.96 Per Share
www.americanbankingnews.com - January 18 at 7:20 AM
Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at Karlskoga, Sweden FacilityCambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at Karlskoga, Sweden Facility
finance.yahoo.com - January 16 at 9:30 AM
Cambrex (CBM) Now Covered by William BlairCambrex (CBM) Now Covered by William Blair
www.americanbankingnews.com - January 16 at 8:08 AM
Cambrex (CBM) Upgraded by Zacks Investment Research to HoldCambrex (CBM) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - January 15 at 8:56 PM
Cambrex Corp. breached its 50 day moving average in a Bearish Manner : CBM-US : January 1, 2018Cambrex Corp. breached its 50 day moving average in a Bearish Manner : CBM-US : January 1, 2018
finance.yahoo.com - January 1 at 9:24 AM
Cambrex Co. (CBM) Receives Consensus Rating of "Hold" from AnalystsCambrex Co. (CBM) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - December 29 at 2:28 AM
Cambrex (CBM) vs. Its Rivals Financial AnalysisCambrex (CBM) vs. Its Rivals Financial Analysis
www.americanbankingnews.com - December 26 at 3:36 PM
Critical Survey: Cambrex (CBM) versus Its RivalsCritical Survey: Cambrex (CBM) versus Its Rivals
www.americanbankingnews.com - December 26 at 9:24 AM
Head-To-Head Review: Cambrex (CBM) & Its RivalsHead-To-Head Review: Cambrex (CBM) & Its Rivals
www.americanbankingnews.com - December 24 at 11:28 PM
Financial Contrast: Cambrex (CBM) vs. Its PeersFinancial Contrast: Cambrex (CBM) vs. Its Peers
www.americanbankingnews.com - December 22 at 3:52 PM
Cambrex (CBM) vs. The Competition Financial SurveyCambrex (CBM) vs. The Competition Financial Survey
www.americanbankingnews.com - December 19 at 5:26 AM
Cambrex (CBM) & Its Peers Head to Head ComparisonCambrex (CBM) & Its Peers Head to Head Comparison
www.americanbankingnews.com - December 18 at 11:08 PM
Reviewing Cambrex (CBM) & The CompetitionReviewing Cambrex (CBM) & The Competition
www.americanbankingnews.com - December 17 at 11:32 AM
Reviewing Cambrex (CBM) & Its RivalsReviewing Cambrex (CBM) & Its Rivals
www.americanbankingnews.com - December 15 at 11:16 PM
Comparing Cambrex (CBM) and Innocoll (INNL)Comparing Cambrex (CBM) and Innocoll (INNL)
www.americanbankingnews.com - December 13 at 1:30 AM
Comparing Cambrex (CBM) & Its PeersComparing Cambrex (CBM) & Its Peers
www.americanbankingnews.com - December 12 at 3:30 PM
Cambrex Corp. breached its 50 day moving average in a Bullish Manner : CBM-US : December 11, 2017Cambrex Corp. breached its 50 day moving average in a Bullish Manner : CBM-US : December 11, 2017
finance.yahoo.com - December 11 at 10:12 AM
ETFs with exposure to Cambrex Corp. : December 5, 2017ETFs with exposure to Cambrex Corp. : December 5, 2017
finance.yahoo.com - December 5 at 5:18 PM
Cambrex Co. (CBM) Receives Average Rating of "Hold" from AnalystsCambrex Co. (CBM) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - December 4 at 1:56 AM
Analyzing Cambrex (CBM) and AMAG Pharmaceuticals (AMAG)Analyzing Cambrex (CBM) and AMAG Pharmaceuticals (AMAG)
www.americanbankingnews.com - December 2 at 9:36 PM
Cambrex (CBM) vs. Its Rivals Head-To-Head ReviewCambrex (CBM) vs. Its Rivals Head-To-Head Review
www.americanbankingnews.com - December 1 at 11:36 PM
Analyzing Cambrex (CBM) & Corium International (CORI)Analyzing Cambrex (CBM) & Corium International (CORI)
www.americanbankingnews.com - December 1 at 11:38 AM
Critical Comparison: Pacira Pharmaceuticals (PCRX) vs. Cambrex (CBM)Critical Comparison: Pacira Pharmaceuticals (PCRX) vs. Cambrex (CBM)
www.americanbankingnews.com - November 30 at 11:42 AM
Head to Head Survey: Cambrex (CBM) and Its RivalsHead to Head Survey: Cambrex (CBM) and Its Rivals
www.americanbankingnews.com - November 29 at 3:28 AM
Comparing Cambrex (CBM) & Adamis Pharmaceuticals (ADMP)Comparing Cambrex (CBM) & Adamis Pharmaceuticals (ADMP)
www.americanbankingnews.com - November 28 at 3:34 PM
Cleantech Building Materials: Distribution and Offtake AgreementCleantech Building Materials: Distribution and Offtake Agreement
finance.yahoo.com - November 23 at 4:07 AM
Corporate News Blog - Puma Biotechnology’s 5-Year Analysis of Phase-III ExteNET Study Gets Published in ‘The Lancet Oncology’Corporate News Blog - Puma Biotechnology’s 5-Year Analysis of Phase-III ExteNET Study Gets Published in ‘The Lancet Oncology’
finance.yahoo.com - November 16 at 12:26 PM
Q4 2017 Earnings Estimate for Cambrex Corporation Issued By First Analysis (CBM)Q4 2017 Earnings Estimate for Cambrex Corporation Issued By First Analysis (CBM)
www.americanbankingnews.com - November 15 at 7:32 AM

SEC Filings

Cambrex (NYSE:CBM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cambrex (NYSE:CBM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cambrex (NYSE CBM) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.